Alios Biopharma, Inc.

Syntex (u.s.a.) Inc.

Roche Palo Alto LLC

Janssen Biopharma, Inc.

Other

Aligos Therapeutics, Inc.

Medivir Ab

Janssen Pharmaceutica Nv

Janssen Pharmaceuticals, Inc.

Jacobs Vehicle Systems, Inc.

Metabasis Therapeutics, Inc.

F. Hoffmann-la Roche Ag

Syntex LLC

Riboscience LLC

Janssen Products, LP

David Bernard Smith

Leonid Beigelman

Guangyi Wang

Jerome Deval

Todd Richard Elworthy

Eric Brian Sjogren

David John Morgans, Jr

David Garrett Loughhead

Ronald Charles Hawley

Peter H Nelson

Robert James Weikert

John W Patterson

Denis John Kertesz

Lawrence M Blatt

Marija Prhavc

Robert Than Hendricks

Alejandra Trejo

Fidencio Franco

Alicia Cervantes

Dean R Artis

Teresa Lara

Ann M Waltos

Natalia Dyatkina

Julian Alexander Symons

Francisco Xavier Talamas

Vivek Kumar Rajwanshi

Joseph Armstrong Martin

Antitsa Dimitrova Stoycheva

Leyi Gong

Robert Stephen Wilhelm

Francisco X Talamas

Mario Fernandez

Yan Lou

Timothy D Owens

Rama K Kondru

Johannes Cornelius Hermann

Keshab Sarma

Nancy Elisabeth Krauss

Nils-Gunnar Johansson

Daisy Joe Du Bois

Taraneh Mirzadegan

Joe Timothy Bamberg

Anna Winqvist

Daisy Joe DuBois

Kevin L McLaren

Francisco X Talam As

Mario Fern Andez

Christian Andreas Jekle

James Patrick Dunn

Mark Smith

Zhou Yang

Keith Adrian Walker

Michael Soth

John C Rohloff

Chris Allen Broka

Neil E Fuchs

Brian L Ruggiero

Wylie Solang Palmer

Vladimir Serebryany

Tobias Gabriel

Hanbiao Yang

Sandrine Vendeville

Jin Hong

Remy Lemoine

Michael G Roepel

Rajendra K Pandey

Andrew Jozef Brzoska

Genaidy Kalyanov

Beihan Wang

Michael P Dailey

James A Judd

Woongki Kim

Scott J Hecker

Christopher McGuigan

K Raja Reddy

Alam Jahangir

Sharada Shenvi Labadie

Hans Maag

Richard E Vanderpoel

Brett C Bookser

Manuel L Karell

Calvin Wesley Yee

Zhili Sun

Steven N Ernest

David Nigel Hurst

Donald Roy Hirschfeld

Min Jiang

Genadiy Kalayanov

Hua Tan

Jaehyeon Park

Tara Lynn Kieffer

Jason Manka

Michael Hunter Welch

Jim W Barnett

Aaron Bayne Miller

Genadiy Kalyanov

Klaus Klumpp

Lars Gj Hammarström

Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

Substituted nucleosides, nucleotides and analogs thereof

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Pyrrole compounds

Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.

The disclosure includes antisense oligonucleotides, including gapmer antisense oligonucleotides, along with methods of making and use, e.g., against HBV.

Modified gapmer oligonucleotides and methods of use

Various embodiments provide STOPS&#x2122; polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS&#x2122; modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS&#x2122; modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.

S-antigen transport inhibiting oligonucleotide polymers and methods

Provided herein are compounds of Formulae (I) and (II), or pharmaceutically acceptable salts of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formulae (I) and/or (II), or a pharmaceutically acceptable salt of any of the foregoing.

Bicyclic sulfonamides

Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.

Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.

Aza-pyridone compounds and uses thereof

AZA-pyridone compounds and uses thereof

Growing community of inventors

San Mateo, CA, United States of America

David Bernard Smith